Page last updated: 2024-09-04

cycloartane and Bone Loss, Osteoclastic

cycloartane has been researched along with Bone Loss, Osteoclastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Dang, NH; Gal, M; Huong, LT; Kim, O; Lee, JH; Nhiem, NX; Tran, PT; Van Kiem, P	1

Other Studies

1 other study(ies) available for cycloartane and Bone Loss, Osteoclastic

Article	Year
Mussaendoside O, a N-triterpene cycloartane saponin, attenuates RANKL-induced osteoclastogenesis and inhibits lipopolysaccharide-induced bone loss. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2022, Volume: 105 Topics: Animals; Bone Resorption; Cell Differentiation; Lipopolysaccharides; Mice; NFATC Transcription Factors; Osteoclasts; Osteogenesis; RANK Ligand; Saponins; Triterpenes	2022

Article

Year

Mussaendoside O, a N-triterpene cycloartane saponin, attenuates RANKL-induced osteoclastogenesis and inhibits lipopolysaccharide-induced bone loss.

Phytomedicine : international journal of phytotherapy and phytopharmacology, 2022, Volume: 105

Topics: Animals; Bone Resorption; Cell Differentiation; Lipopolysaccharides; Mice; NFATC Transcription Factors; Osteoclasts; Osteogenesis; RANK Ligand; Saponins; Triterpenes

2022